Drugs / rhIL-2
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00005655 | Apr 2000 → Oct 2010 | breast neoplasm, kidney neoplasm, lung neoplasm, sarcoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02411253 | Jun 2015 → Nov 2020 | type 1 diabetes mellitus | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03069534 | Jun 2009 → Jun 2019 | multidrug-resistant tuberculosis | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02955550 Background | Jan 2017 → Jul 2018 | plasma cell myeloma | Celularity Incorporated | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhIL-2 | “The patients in rhIL-2 group were given consisted of four courses of low-dose rhIL-2 (500，000 U/m) given subcutaneously (SC) once every other day (q.o.d.) for 30 days.” NCT03069534 ↗ |
| Known as | recombinant human interleukin-2 | “Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB” NCT03069534 ↗ |
| Action | Restore | “IL-2 therapy regimans are expected to restore the immune response” NCT03069534 ↗ |
| Modality | Protein / enzyme biologic | “intermittent pulse recombinant human IL-2” NCT00005655 ↗ |
| Route | Intravenous | “rhIL-2 will be administered intravenously” NCT00005655 ↗ |